Adjunctive Risperidone Treatment for Antidepressant-Resistant Symptoms of Chronic Military Service–Related PTSD | Zendy

John H. Krystal | Zendy; Robert A. Rosenheck | Zendy; Joyce A. Cramer | Zendy; Jennifer C. Vessicchio | Zendy; Karen Jones | Zendy; Julia E. Vertrees | Zendy; Rebecca A. Horney | Zendy; Grant D. Huang | Zendy; Christopher Stock | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Adjunctive Risperidone Treatment for Antidepressant-Resistant Symptoms of Chronic Military Service–Related PTSD

Author(s) -

John H. Krystal,

Robert A. Rosenheck,

Joyce A. Cramer,

Jennifer C. Vessicchio,

Karen Jones,

Julia E. Vertrees,

Rebecca A. Horney,

Grant D. Huang,

Christopher Stock

Publication year - 2011

Publication title -

jama

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 4.688

H-Index - 680

eISSN - 1538-3598

pISSN - 0098-7484

DOI - 10.1001/jama.2011.1080

Subject(s) - medicine , risperidone , clinical global impression , placebo , psychiatry , hamilton anxiety rating scale , randomized controlled trial , context (archaeology) , escitalopram , atypical antipsychotic , anxiety , antidepressant , antipsychotic , schizophrenia (object oriented programming) , alternative medicine , pathology , paleontology , biology

Serotonin reuptake-inhibiting (SRI) antidepressants are the only FDA-approved pharmacotherapies for the treatment of posttraumatic stress disorder (PTSD).

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research